Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles

Japanese Journal of Cancer Research

Volumn 90, Issue 1, 1999, Pages 122-128

  Matsumura, Yasuhiro ^a   Yokoyama, Masayuki ^b   Kataoka, Kazunori ^c   Okano, Teruo ^b   Sakurai, Yasuhisa ^b   Kawaguchi, Takanori ^d   Kakizoe, Tadao ^e  

^a Department of Medicine ^*  (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

DDS; KRN5500; Micelles

Indexed keywords

6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; ANTINEOPLASTIC AGENT; DRUG CARRIER; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; DRUG SOLUTION; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER NECROSIS; MICELLE; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0033042635     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00675.x     Document Type: Article

References (21)

1. Matsumura, Y. and Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smanes. Cancer Res., 46, 6387-6392 (1986).
2. Dvorak, H. F., Nagy, J. A., Dvorak, J. T. and Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133, 95-109 (1988).
3. Maeda, H. and Matsumura, Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst., 6, 193-210 (1989).
4. Matsumura, Y., Maruo, K., Kimura, M., Yamamoto, T., Konno, T. and Maeda, H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res., 82, 732-741 (1991).
5. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med., 1, 27-31 (1995).
6. Kamishohara, M., Kawai, H., Sakai, T., Isoe, T., Hasegawa, K., Mochizuki, J., Uchida, T., Kataoka, S., Yamaki, H., Tsuruo, T. and Otake, N. Antitumor activity of a Spicamycin derivative. KRN5500, and its active metabolite in tumor cells. Oncol. Res., 6, 383-390 (1994).
7. Yokoyama, M., Satoh, A., Sakurai, Y., Okano, T., Matsumura, Y., Kakizoe, T. and Kataoka, K. Incorporation of water-insoluble anticancer drug into polymeric micelles and control of their particle size. J. Controlled Release (1998), in press.
8. Yoshimoto, T., Nishimura, H., Saito, Y., Sakurai, K., Kamisaki, Y., Wada, H., Sako, M., Tsujino, G. and Inada, Y. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn. J. Cancer Res., 77, 1264-1270 (1986).
9. Konno, T., Maeda, H., Iwaki, K., Maki, S., Tashiro, S., Uchida, M. and Miyauchi, Y. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer, 54, 2367-2374 (1984).
10. Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., Rarick, Mu., Myers, A. M., Shepherd, F., Sawka, C., Pike, M. C. and Ross, M. E. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol., 14, 2353-2364 (1996).
11. Northfelt, D. W., Dezube, B. J., Thommes, J. A., Levine, R., von Roenn, J. H., Dosik, G. M., Rios, A., Krown, S. E., DuMond, C. and Mamelok, R. D. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol., 15, 653-659 (1997).
12. Lasic, D. D. Doxorubicin in sterically stabilized liposomes. Nature, 380, 561-562 (1996).
13. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A. and Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 54, 987-992 (1994).
14. Duncan, R., Hume, I. C., Kopeckova, P., Ulbrieh, K., Strohalm, J. and Kopecek, J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers 3. Evaluation of adriamycin conjugates against mouse leukemia L1210 in vivo. J. Controlled Release, 10, 51-63 (1989).
15. Seymour, L. W., Ulbrieh, K., Sleyger, P. S., Brereton, M., Subr, V., Strohalm, J. and Duncan, R. Tumor tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16 F10 melanoma. Br. J. Cancer. 70, 636-641 (1994).
16. Yokoyama, M., Miyauchi, M., Yamada, N., Okano, T., Sakurai, Y., Kataoka, K. and Inoue, S. Polymeric micelle as novel carrier: adriamycin-conjugated poly(ethyleneglycol)-poly(aspartic acid) block copolymer. J. Controlled Release, 11, 269-278 (1990).
17. Dorn, K., Hoerpel, G. and Ringsdorf, H. Polymer antitumor agents at a molecular and cellular level. In "Bioactive Polymeric Systems: An Overview," ed. C. G. Gebelein and C. E. Carraher, pp. 531-585 (1985). Plenum Press, New York.
18. Yokoyama, M., Fukushima, S., Uehara, R., Okamoto, K., Kataoka, K., Sakurai, Y. and Okano, T. Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J. Controlled Release, 50, 79-92 (1998).
19. Kwon, G. S., Yokoyama, M., Okano, T., Sakurai, Y. and Kataoka, K. Biodistribution of micelle forming polymer-drug conjugate. Pharm. Res., 10, 970-974 (1993).
20. Katre, N. V., Knauf, M. J. and Laird, W. J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl. Acad. Sci. USA, 84, 1487-1491 (1987).
21. Yokoyama, M., Okano, T., Sakurai, Y., Ekimoto, H., Shibazaki, C. and Kataoka, K. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res., 51, 3229-3236 (1991).